N-acetylgalactosaminyltransferase : a potential target for colorectal adenocarcinoma
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 12(2020), 17 vom: 08. Sept., Seite 1529-1531 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prasher, Parteek [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9DLQ4CIU6V |
|---|
| Anmerkungen: |
Date Completed 14.07.2021 Date Revised 14.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2020-0137 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313281238 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313281238 | ||
| 003 | DE-627 | ||
| 005 | 20231225150235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2020-0137 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313281238 | ||
| 035 | |a (NLM)32752887 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prasher, Parteek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a N-acetylgalactosaminyltransferase |b a potential target for colorectal adenocarcinoma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2021 | ||
| 500 | |a Date Revised 14.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a GalNAc-Ts | |
| 650 | 4 | |a colorectal adenocarcinoma | |
| 650 | 4 | |a mucin | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 650 | 7 | |a N-Acetylgalactosaminyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.4.1.- |2 NLM | |
| 650 | 7 | |a Sarcosine |2 NLM | |
| 650 | 7 | |a Z711V88R5F |2 NLM | |
| 700 | 1 | |a Sharma, Mousmee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 12(2020), 17 vom: 08. Sept., Seite 1529-1531 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:17 |g day:08 |g month:09 |g pages:1529-1531 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2020-0137 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 17 |b 08 |c 09 |h 1529-1531 | ||